John M. Siebert - 22 Feb 2024 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
26 Feb 2024, 17:01:53 UTC
Prior SEC filing
27 Feb 2023
Next SEC filing
27 Feb 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Timothy C. Dec, as attorney-in-fact

Key filing fact

John M. Siebert filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 26 Feb 2024.

Key facts

  • This page summarizes John M. Siebert's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 26 Feb 2024, 17:01.

Change

  • Previous filing in this sequence was filed on 27 Feb 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SUPN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
84,057
Date
22 Feb 2024
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SUPN transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+8,252
Change %
Price
$0.000000
Shares after
8,252
Date
22 Feb 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
8,252
Exercise price
$27.94
Footnotes
F1
SUPN transaction Derivative

Restricted Stock Units

Award

Transaction value
$0
Shares
+5,369
Change %
Price
$0.000000
Shares after
5,369
Date
22 Feb 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
5,369
Exercise price
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The option vests on February 22, 2025.

Footnote F2

Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

Footnote F3

These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .